Page last updated: 2024-12-05

9,10-anthraquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9,10-Anthraquinone is a bright yellow, crystalline organic compound with the formula C14H8O2. It is a highly important synthetic intermediate in the production of dyes, pigments, and pharmaceuticals. Its synthesis typically involves the oxidation of anthracene, a common starting material. 9,10-Anthraquinone exhibits various biological effects, including anti-inflammatory, antioxidant, and anticancer properties. It is also used in the synthesis of important pharmaceutical compounds, such as anthracycline antibiotics. Extensive research on 9,10-anthraquinone focuses on its potential applications in medicine, materials science, and organic electronics due to its unique electronic and optical properties.'

9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6780
CHEMBL ID55659
CHEBI ID40448
SCHEMBL ID14943
MeSH IDM0126292

Synonyms (120)

Synonym
AC-12719
hoelite
anthradione
anthraquinone
9,10-dioxoanthracene
84-65-1
anthracene,10-dihydro-9,10-dioxo-
9,10-anthraquinone
morkit
9,10-anthracenedione
nsc7957
nsc-7957
DIVK1C_006741
SPECTRUM_001527
SPECTRUM5_001897
inchi=1/c14h8o2/c15-13-9-5-1-2-6-10(9)14(16)12-8-4-3-7-11(12)13/h1-8
anthracene-9,10-dione
anthra-9,10-quinone
nsc 7957
9,10-dihydro-9,10-dioxoanthracene
einecs 201-549-0
anthracene, 9,10-dihydro-9,10-dioxo-
9,10-anthrachinon [czech]
anthraquinone [bsi:iso]
corbit
hsdb 2074
epa pesticide chemical code 122701
ai3-09073
ccris 649
anthrapel
caswell no. 052a
anthraquinone, 97%
CHEBI:40448 ,
az-q
9,10-quinone
9,10-anthracendion
9,10-anthrachinon
anthrachinon
9TA ,
1,4-bis-[2-(2-hydroxy-ethylamino)-ethylamino]-anthraquinone
NCGC00094960-01
NCGC00094960-02
NCGC00094960-03
KBIOGR_001374
KBIO2_007143
KBIO1_001685
KBIO2_004575
KBIO3_002641
KBIOSS_002007
KBIO2_002007
SPECPLUS_000645
SPECTRUM2_000405
SPECTRUM4_000907
SPECTRUM3_001501
SPBIO_000330
SPECTRUM1502103
BSPBIO_003141
NCGC00094960-04
STK398385
A0502
bdbm50094892
AKOS000282964
CHEMBL55659 ,
HMS1921J14
030ms0jbdo ,
unii-030ms0jbdo
ec 201-549-0
dtxcid9095
tox21_111369
dtxsid3020095 ,
cas-84-65-1
CCG-39966
anthracene-9,10-quinone
FT-0622417
kawasaki saq
avipel
AB-131/40003277
EPITOPE ID:116191
anthraquinone [mi]
SAQ ,
anthraquinone [hsdb]
anthraquinone [iso]
flight control
anthraquinone [inci]
anthraquinone [iarc]
S5168
A-8000
SCHEMBL14943
NCGC00094960-06
tox21_111369_1
anthra-9,10-quinone #
mfcd00001188
melting point standard 283-286c, analytical standard
SR-01000944707-1
sr-01000944707
anthraquinone, pestanal(r), analytical standard
anthraquinone, purum, >=99.0% (hplc)
anthraquinone, vetec(tm) reagent grade, 97%
anthraquinone, analytical standard
anthraquinone 100 microg/ml in acetonitrile
9,10-anthraguinone
F0001-2133
9,10-dihydroanthracene-9,10-dione
DS-4810
Q423174
HY-N0354
BRD-K15957397-001-03-4
9,10-anthraquinone;9,10-anthracenedione;anthraquinone;anthracene-9,10-dione;9,10-anthraquinone 9,10-anthracenedione anthraquinone anthracene-9,10-dione
an anthraquinone derivative
dioxoanthracene
CS-0008907
EN300-71612
71730-08-0
Z1142688857
anthraquinone (iarc)
9,10-dihydro-9,10-diketoanthracene
usepa/opp pesticide code: 122701
9,10-anthracendione
(p) anthrapel
anthracenequinones

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The toxic effect of ANTQ on this strain was more pronounced in high-CO2 cells, where not only growth but also photosynthesis, respiration and SOD activity were significantly inhibited."( Toxic effects of anthraquinone and phenanthrenequinone upon Scenedesmus strains (green algae) at low and elevated concentration of CO2.
Aksmann, A; Tukaj, Z, 2007
)
0.34
" A no observed adverse effect level of 469 ppm AQ (31."( Subchronic toxicity evaluation of anthraquinone in Fischer 344 rats.
Cantwell, KE; Dodd, DE; Layko, DK; Thomas, RS; Willson, GA,
)
0.13
" Previous studies focused on the kinetics and the microbial actions of PCP degradation, however, the effects of toxic and antimicrobial PCP and electron donor/shuttle on the microbial community diversity and composition in paddy soil are poorly understood."( Microbial community response to the toxic effect of pentachlorophenol in paddy soil amended with an electron donor and shuttle.
Chen, M; Gao, Y; Jiang, Q; Liu, C; Lv, Y; Qiao, J; Tong, H, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" This method was successfully applied to the analysis of the three drugs in rat plasma and their pharmacokinetic studies."( Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride.
Cui, S; Feng, F; Liu, H; Ma, M; Xie, D; Xu, S, 2007
)
0.54

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID485281
RAR-related orphan receptor gammaMus musculus (house mouse)Potency4.98040.006038.004119,952.5996AID1159521; AID1159523
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency4.91900.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency3.66250.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency35.48130.000817.505159.3239AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.76570.001530.607315,848.9004AID1224841; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency27.11320.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.91200.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID743069; AID743080; AID743091
Histone H2A.xCricetulus griseus (Chinese hamster)Potency26.95730.039147.5451146.8240AID1224845
histone deacetylase 9 isoform 3Homo sapiens (human)Potency5.48300.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency15.81680.000627.21521,122.0200AID651741; AID720636
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency3.21970.005612.367736.1254AID624032
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency2.90810.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency2.90810.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)122.00000.00002.37899.7700AID1888748
Dual specificity protein phosphatase 1Mus musculus (house mouse)IC50 (µMol)50.00008.45008.91009.3700AID417087
M-phase inducer phosphatase 2Homo sapiens (human)IC50 (µMol)9.51000.10002.31039.5100AID417086
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.600310.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.630610.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00061.525710.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.747210.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.741110.0000AID144609; AID144610
Dual specificity protein phosphatase 6Rattus norvegicus (Norway rat)IC50 (µMol)50.00006.90006.90006.9000AID417088
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.741110.0000AID144609; AID144610
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)IC50 (µMol)100.00000.00251.14809.2000AID1374899
Histone-lysine N-methyltransferase EHMT1Homo sapiens (human)IC50 (µMol)100.00000.01300.79954.9000AID1374900
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.741110.0000AID144609; AID144610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
oocyte maturationM-phase inducer phosphatase 2Homo sapiens (human)
protein phosphorylationM-phase inducer phosphatase 2Homo sapiens (human)
female meiosis IM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cell population proliferationM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cytokinesisM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
cell divisionM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to starvationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of DNA replicationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
synaptonemal complex assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
spermatid developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
long-term memoryHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
fertilizationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of protein modification processHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
organ growthHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
phenotypic switchingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
behavioral response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
oocyte developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
neuron fate specificationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to xenobiotic stimulusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of autophagosome assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
regulation of embryonic developmentHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 2Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
enzyme bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K56 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
spindle poleM-phase inducer phosphatase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 2Homo sapiens (human)
centrosomeM-phase inducer phosphatase 2Homo sapiens (human)
cytosolM-phase inducer phosphatase 2Homo sapiens (human)
nucleusM-phase inducer phosphatase 2Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nuclear speckHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nuclear bodyHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (92)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID417086Inhibition of histidine-tagged human recombinant Cdc25B catalytic domain expressed in Escherichia coli2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
AID1102422Phytotoxicity in Solanum lycopersicum (tomato) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 94 +/- 2%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1374901Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1083211Bactericidal activity against Erwinia amylovora 295/93 assessed as growth inhibition in King's B full medium measured at pH 7.2 after overnight incubation by suspension culture assay2012Journal of agricultural and food chemistry, Dec-12, Volume: 60, Issue:49
Potent and specific bactericidal effect of juglone (5-hydroxy-1,4-naphthoquinone) on the fire blight pathogen Erwinia amylovora.
AID1102414Phytotoxicity in Lactuca sativa (lettuce) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 90 +/- 5.3%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1102423Antifungal activity against Botryotinia fuckeliana assessed as inhibition of conidia germination at 1 to 10 ug/mL after 5 hr by light adverse phase microscopic analysis2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID729919Cytotoxicity against human AGS cells assessed as cell viability after 72 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Annulation of substituted anthracene-9,10-diones yields promising selectively antiproliferative compounds.
AID1102416Phytotoxicity in Brassica oleracea (broccoli) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 90.7 +/- 4.2%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1102426Antifungal activity against Sclerotinia minor assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1888752Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate at 100 uM after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID144609Displacement of [3H]MK-801 from N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex.
AID1102425Antifungal activity against Sclerotinia sclerotiorum assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1102421Phytotoxicity in Capsicum annuum (pepper) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 84.7 +/- 4.6%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1435048Displacement of fluorescein-neomycin from d(G4C4)2 DNA at 200 nM by fluorescence assay2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Probing A-form DNA: A fluorescent aminosugar probe and dual recognition by anthraquinone-neomycin conjugates.
AID1536188Inhibition of PDK4 (unknown origin) at 1 uM relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.
AID417089Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
AID1102417Phytotoxicity in Brassica oleracea (cabbage) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 90 +/- 5.3%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1374895Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374899Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID729915Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Annulation of substituted anthracene-9,10-diones yields promising selectively antiproliferative compounds.
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID102411Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 3 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID729917Cytotoxicity against human J82 cells assessed as cell viability after 72 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Annulation of substituted anthracene-9,10-diones yields promising selectively antiproliferative compounds.
AID1374898Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID144610Displacement of [3H]-SPD from N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex.
AID1112558Phytotoxicity against Zea mays (maize) seeds assessed as germination rate at 25 degC after 5-6 days by standard vigour method2013Pest management science, Mar, Volume: 69, Issue:3
Assessing the effects of three potential chemical repellents to prevent bird damage to corn seeds and seedlings.
AID1102419Phytotoxicity in Cucumis melo (muskmelon) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 90 +/- 2%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID398698Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced oxygen consumption up to 0.3 mM relative to control1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID1374900Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID343962Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID398699Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced malondialdehyde formation up to 0.3 mM relative to control1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID1102415Phytotoxicity in Brassica oleracea var. italica assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 97.3 +/- 1.2%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID729920Cytotoxicity against human MRC5 cells assessed as cell viability after 72 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Annulation of substituted anthracene-9,10-diones yields promising selectively antiproliferative compounds.
AID417087Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
AID1102424Antifungal activity against Verticillium dahliae assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1374902Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID417088Inhibition of histidine-tagged rat recombinant MKP3 catalytic domain expressed in Escherichia coli BL21(DE3)2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1102418Phytotoxicity in Solanum melongena (eggplant) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 84.7 +/- 2.3%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1112566Bird repellent activity against Columba livia f. domestica fed with compound treated maize seeds assessed as feeding deterrence activity at 1 ml/kg by aviary food choice trials2013Pest management science, Mar, Volume: 69, Issue:3
Assessing the effects of three potential chemical repellents to prevent bird damage to corn seeds and seedlings.
AID1374896Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1102420Phytotoxicity in Cucumis sativus (cucumber) assessed as seed germination at 250 mg/mL applied as seed dressings after 8 to 14 days (Rvb = 94.7 +/- 1.2%)2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1112559Phytotoxicity against Zea mays (maize) seeds assessed as germination rate at 10 degC after 7 days by standard vigour method2013Pest management science, Mar, Volume: 69, Issue:3
Assessing the effects of three potential chemical repellents to prevent bird damage to corn seeds and seedlings.
AID1102427Antifungal activity against Botryotinia fuckeliana assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1374897Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID729918Cytotoxicity against human SKMES1 cells assessed as cell viability after 72 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Annulation of substituted anthracene-9,10-diones yields promising selectively antiproliferative compounds.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (293)

TimeframeStudies, This Drug (%)All Drugs %
pre-199084 (28.67)18.7374
1990's12 (4.10)18.2507
2000's40 (13.65)29.6817
2010's100 (34.13)24.3611
2020's57 (19.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.98 (24.57)
Research Supply Index5.71 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index48.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (2.66%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other293 (97.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]